Small molecule compounds as JAK kinase inhibitors and their uses

Small molecule compounds targeting JAK1/Tyk2 kinases provide effective treatments for autoimmune diseases and inflammatory skin diseases by inhibiting JAK kinase activity, addressing the limitations of current treatments and reducing systemic side effects.

JP7587887B2Active Publication Date: 2024-11-21TECHNODERMA MEDICINES
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
JP2023521674
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-10-09
Filing Date
2021-09-24
Publication Date
2024-11-21
Estimated Expiration
2041-09-24

AI Technical Summary

Technical Problem

Current treatments for autoimmune diseases and inflammatory skin diseases lack effective, non-systemic inhibitors that can target JAK kinases without causing significant side effects, and existing JAK inhibitors are challenging to develop due to the complexity of multiple JAK pathways involved in these conditions.

Method used

Development of small molecule compounds that act as JAK1/Tyk2 dual inhibitors and Tyk2-specific inhibitors, designed to target specific JAK kinases, with IC50 values below 200nM, to inhibit JAK kinase activity and provide targeted treatments for autoimmune diseases and inflammatory skin diseases.

Benefits of technology

The compounds demonstrate potent inhibitory effects on JAK kinases, offering therapeutic benefits for conditions like rheumatoid arthritis, psoriasis, and eczema while minimizing systemic side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007587887000001
    Figure 0007587887000001
  • Figure 0007587887000002
    Figure 0007587887000002
  • Figure 0007587887000003
    Figure 0007587887000003
Patent Text Reader

Abstract

The present invention provides a small molecule compound represented by the following formula (I), or a stereoisomer, geometric isomer, tautomer, hydrate, solvate, or pharmaceutically acceptable salt or prodrug thereof, wherein R1 to R5 are each independently selected from C or N; and R is selected from cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, aryl, substituted aryl, heteroaryl, or substituted heteroaryl. The small molecule compound according to the present invention can inhibit JAK kinases, particularly as a JAK1 / Tyk2 dual inhibitor and a Tyk2-specific inhibitor. TIFF2023545784000028.tif3570
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] [CROSS REFERENCE TO THIS APPLICATION] This invention claims priority to a patent application with application number CN202011072699.4, filed on October 9, 2020, and entitled "Small molecule compounds as JAK kinase inhibitors and their uses."

[0002] [Technical field] The present invention is in the field of small molecule compounds, and in particular relates to small molecule compounds that are used to prevent, treat or alleviate autoimmune diseases such as rheumatoid arthritis, ulcerative colitis and systemic lupus erythematosus, or related inflammatory skin diseases such as psoriasis, eczema, vitiligo and alopecia areata. [Background technology]

[0003] JAK (Janus Kinase) is a family of intracellular non-receptor tyrosine kinases, including four members: JAK1, JAK2, JAK3, and Tyk2. The JAK-STAT (Signal Transducer and Activator of Transcription proteins) signal transduction pathway is the main intracellular transduction pathway of signals triggered by the combination of inflammatory cytokines and receptors. A large body of evidence indicates that the JAK-STAT signal transduction pathway plays an essential driving role in the pathogenesis of many diseases, especially autoimmune diseases such as rheumatoid arthritis, lupus erythematosus, inflammatory bowel disease, multiple sclerosis, Sjogren's syndrome, psoriasis, alopecia areata, and vitiligo, and allergic diseases such as asthma, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, and eczema. Therefore, the use of highly efficient small molecules to inhibit JAK kinase activity, particularly JAK1, TYK2 kinase activity, can block cytokine-mediated signaling pathways involved in inflammatory responses, thereby suppressing inflammation and effectively treating autoimmune and / or allergic inflammatory diseases.

[0004] In the development process of different inflammatory diseases, T cells differentiate in different directions by different inflammatory inducers such as virus or bacterial infection, generating T cell subsets such as Th1, Th2, and Th17, and these T cells produce various cytokines accordingly. For example, Th1 cells associated with acute inflammation caused by virus infection produce IFNγ and IL-2, Th2 cells associated with allergy produce IL-4, IL-5, and IL-13, and Th17 cells associated with autoimmunity produce IL-17, IL-12, IL-21, IL-22, and IL-23. These cytokines bind to receptors on the cell surface and transmit inflammatory signals through intracellular JAK to promote the pathological process of the disease. More importantly, many inflammatory diseases with unknown etiology have been revealed to have complex mechanisms involving multiple T cell subsets at different or the same stage. In other words, multiple JAK pathways are involved, presenting new requirements for the development of therapeutic drugs for inflammatory diseases targeting JAK.

[0005] Some studies have reported that JAK1 inhibitors can specifically inhibit Th2-based allergic inflammation, but there are few reports on the effective inhibition of JAK1 and / or TYK2 inhibitors. However, we believe that JAK1 / Tyk2 dual inhibitors and Tyk2 inhibitors have a broader clinical perspective, especially in inflammatory diseases caused by autoimmune abnormalities. In addition, since multiple JAKs may be involved in the pathogenesis of more inflammatory diseases, especially inflammatory skin diseases, it is very important to develop a strong single or dual inhibitor of JAK1 and Tyk2, especially in the topical treatment of skin diseases, a strong inhibitor can not only have excellent therapeutic effects, but also avoid the side effects caused by systematic dosing, but this requires strong activity inhibition at the same time. Summary of the Invention

[0006] The purpose of the present invention is to obtain a highly efficient JAK1 / Tyk2 dual inhibitor and Tyk2 specific inhibitor, and provide targeted treatment for different inflammatory diseases.For example, JAK1 / Tyk2 dual inhibitor may be suitable for SLE, vitiligo, IBD, eczema and other inflammatory diseases, and Tyk2 specific inhibitor is more suitable for the treatment of rheumatoid arthritis, psoriasis, alopecia areata, etc., and at the same time, it may overcome the hematopoietic inhibition and coagulation abnormality caused by the inhibition of JAK2.In addition, the JAK family inhibitor suitable for external use such as inflammatory skin disease can be selected according to the etiology and symptoms, and can be intervened in the disease to suppress the symptoms, thereby obtaining good therapeutic effect.

[0007] To achieve the above object, in one aspect, the present invention provides a small molecule compound represented by the following formula I, or a stereoisomer, geometric isomer, tautomer, hydrate, solvate, and pharma- ceutically acceptable salt or prodrug thereof: [ka] Where: R1 to R5 are each independently selected from C or N; R is selected from cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, aryl, substituted aryl, heteroaryl, or substituted heteroaryl.

[0008] In one embodiment, a maximum of two of R1 to R5 are N.

[0009] In another embodiment, R has a structure represented by formula II: [ka] Where: R6 is selected from C or N; R7 is selected from hydrogen, halogen, alkyl, amino, amido, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R8 is selected from hydrogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl.

[0010] In another embodiment, R7 and R8 are each independently selected from hydrogen, alkyl, or cycloalkyl.

[0011] In another embodiment, R has a structure represented by formula III: [ka] Where: R9 is selected from C or N; R 10 is selected from hydrogen, halogen, alkyl, amino, amido, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; R 11 is selected from hydrogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl.

[0012] In another embodiment, R 10 and R 11 are each independently selected from hydrogen, alkyl, or cycloalkyl.

[0013] In another embodiment, the alkyl group is methyl, ethyl, propyl, or isopropyl, and the cycloalkyl group is cyclopropyl, cyclobutyl, or cyclopropylmethyl.

[0014] In another aspect, the present invention further provides the use of the small molecule compounds described above in the inhibition of JAK kinases.

[0015] In another aspect, the present invention further provides the use of the small molecule compound as described above in the preparation of a medicament for preventing or treating JAK-associated autoimmune diseases and immune-related inflammatory skin diseases.

[0016] In one embodiment, the autoimmune disease is selected from at least one of rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, Crohn's disease, systemic lupus erythematosus, dermatomyositis, multiple sclerosis, type I diabetes, Sjogren's syndrome, and vasculitis.

[0017] In another embodiment, the immune-related inflammatory skin disease is selected from at least one of atopic dermatitis, eczema, alopecia areata, psoriasis, vitiligo, lichen planus, lichen nitidus, lichen sclerosus, panniculitis, acne, and hidradenitis suppurativa.

[0018] The functions and advantages of the present invention are as follows: The present invention involves the deliberate and rational design of small molecule compounds according to the protein structure of JAK kinases, particularly that of Tyk2. The synthesized compounds were first tested for biochemical activity of JAK kinases and were then shown to have IC 50 Establishes structure-activity relationship (SAR) and has an IC of less than 200 nM 50 The potent inhibitors having the above structure were subjected to cytological testing to determine the selectivity of the compounds. Referring to the specific activity experimental data, it can be seen that the compounds involved in the present invention have good JAK kinase activity and cell biological activity inhibition ability. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0019] Hereinafter, specific embodiments of the present invention will be described in detail. It should be understood that the specific embodiments described herein are only used for the purpose of explaining and interpreting the present invention, and are not intended to limit the present invention.

[0020] It should be understood that the endpoints of the ranges and any values ​​disclosed herein are not limited to the exact ranges or values, and that these ranges or values ​​include values ​​approaching these ranges or values. In the case of numerical ranges, it is possible to combine the endpoints of each range, the endpoints of each range and the individual point values, and the individual point values ​​with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed herein.

[0021] Before describing the invention in detail, it should be understood that the terms used herein are for describing particular embodiments and are not intended to limit the scope of the invention, which is defined solely by the appended claims. In order to provide a more complete understanding of the invention described herein, the following terms are used and are defined as follows: Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0022] In one aspect, the present invention provides a small molecule compound that is represented by Formula I: [ka] Where: R1 to R5 are each independently selected from C or N; R is selected from cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, aryl, substituted aryl, heteroaryl, or substituted heteroaryl.

[0023] That is, R1, R2, R3, R4 and R5 may each be independently selected from C or N. In a preferred embodiment, up to three of R1 to R5 (i.e., 0, 1, 2 or 3) may be N. In a preferred embodiment, up to two of R1 to R5 (i.e., 0, 1 or 2) may be N. In another preferred embodiment, up to one of R1 to R5 (i.e., 0 or 1) may be N.

[0024] According to the present invention, in a preferred embodiment, R may have a structure represented by formula II shown below. [ka] Where: R6 may be selected from C or N; R7 may be selected from hydrogen, halogen, alkyl, amino, amido, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; R8 may be selected from hydrogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl.

[0025] In a more preferred embodiment, R7 and R8 may each independently be selected from hydrogen, alkyl, or cycloalkyl, wherein the alkyl may be methyl, ethyl, propyl, or isopropyl, and the cycloalkyl may be cyclopropyl, cyclobutyl, or cyclopropylmethyl.

[0026] For example, in a specific embodiment, R6 is C, R7 is hydrogen, and R8 is ethyl, in which case R can have the structure shown below. [ka]

[0027] For example, in a specific embodiment, R6 is N, R7 is methyl, and R8 is methyl, in which case R can have the structure shown below. [ka]

[0028] For example, in a specific embodiment, R6 is C, R7 is methyl, and R8 is ethyl, in which case R can have the structure shown below. [ka]

[0029] For example, in a specific embodiment, R6 is N, R7 is methyl, and R8 is hydrogen, in which case R can have the structure shown below. [ka]

[0030] According to another preferred embodiment of the present invention, R has a structure represented by formula III shown below. [ka] Where: R9 is selected from C or N; R 10 is selected from hydrogen, halogen, alkyl, amino, amido, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; R 11 is selected from hydrogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl.

[0031] In a more preferred embodiment, R 10 and R 11 are each independently selected from hydrogen, alkyl, or cycloalkyl, and further, said alkyl groups are methyl, ethyl, propyl, or isopropyl, and said cycloalkyl groups are cyclopropyl, cyclobutyl, or cyclopropylmethyl.

[0032] For example, in specific embodiments, R is N and R 10 is hydrogen, and R 11 is methyl. In this case, R can have the structure shown below. [ka]

[0033] According to the present invention, in another preferred embodiment, R can further have the structure shown below. [ka]

[0034] The term "pharmacologically acceptable" as used herein refers to a substance that does not affect the biological activity or properties of the compound according to the present invention and is relatively non-toxic. That is, the substance can be administered to an individual without causing adverse biological reactions or interacting undesirably with any of the components contained in the composition. In the present invention, "pharmacologically acceptable salts" include inorganic salts and organic salts, including but not limited to ammonium, lithium, sodium, potassium, cesium, calcium, magnesium, copper, aluminum, zinc, barium, or quaternary ammonium salts; inorganic salts include but are not limited to arginine, tert-butylamine, dimethylamine, diethanolamine, ethanolamine, ethylenediamine, imidazole, lysine, methylamine, pyridine, pyridine carboxylic acid ester, piperazine, triethylamine, triethanolamine, trimethylamine, or urea salts.

[0035] In another aspect, the present invention provides the use of the small molecule compounds as described above for inhibiting JAK kinases, particularly as dual JAK1 / Tyk2 inhibitors and Tyk2 specific inhibitors.

[0036] In another aspect, the present invention further provides a use of the small molecule compound in the preparation of a medicament for preventing or treating autoimmune diseases and immune-related inflammatory skin diseases, the pathogenesis of which has been shown to be related to dysregulation of JAK signaling.

[0037] The term "treatment" as used herein means that any administration of a therapeutic agent according to a treatment regimen results in the desired effect, i.e., partial or complete alleviation, amelioration, mitigation, inhibition, delay of onset, reduction in severity, and / or reduction in incidence of one or more symptoms or characteristics of a particular disease, disorder, and / or condition. In some embodiments, administration of a therapeutic agent according to a treatment regimen is associated with achieving a desired effect. Such treatment may be directed to subjects who do not exhibit the relevant disease, disorder, and / or condition, and / or subjects who exhibit only early signs of the disease, disorder, and / or condition. Alternatively or additionally, such treatment may be directed to subjects who exhibit one or more identified signs of the relevant disease, disorder, and / or condition. In some embodiments, treatment may be directed to subjects who have been diagnosed with the relevant disease, disorder, and / or condition. In some embodiments, treatment may be directed to subjects who have one or more predisposing factors statistically associated with an increased risk of developing the relevant disease, disorder, and / or condition.

[0038] According to the present invention, the medicament prepared for the above uses may comprise an effective amount of a small molecule compound according to the present invention and a pharma- ceutically acceptable excipient, carrier or diluent.

[0039] As used herein, the term "effective amount," "therapeutically effective amount," or "pharmaceutical effective amount" refers to an amount of a therapeutic agent that confers a therapeutic effect on the treated subject, at a reasonable benefit / risk ratio appropriate for any drug treatment. Such therapeutic effect may be objective (i.e., measurable by some test or indication) or subjective (i.e., effect as reported or felt by the subject). In some embodiments, a "therapeutically effective amount" refers to an amount of a therapeutic agent or composition that effectively treats, ameliorates, or prevents (e.g., delays onset of) the associated disease or condition, and / or exhibits a detectable therapeutic or prophylactic effect, such as by ameliorating symptoms associated with the disease, preventing or delaying the onset of the disease, and / or reducing the severity or frequency of symptoms of the disease.

[0040] Those skilled in the art will recognize that the therapeutically effective amount of the small molecule compound administered will vary depending on the subject and the nature and severity of the disease, the subject's physical condition, the treatment regimen (e.g., with or without the use of a second therapeutic agent), and the selected route of administration. The appropriate dosage can be easily determined by those skilled in the art. Meanwhile, the optimal number and interval of individual administrations of the drug will be determined by the nature and extent of the pathology being treated, the form, route and site of administration, the age and pathology of the particular subject being treated, and the appropriate dosage will ultimately be determined by the physician. This dosage may be repeated multiple times as necessary, and if side effects occur, the amount and / or frequency of administration may be modified or reduced in accordance with normal clinical practice.

[0041] In the present invention, a "pharmaceutically acceptable excipient, carrier, or diluent" includes, but is not limited to, any adjuvant, carrier, excipient, glidant, sweetener, diluent, preservative, dye / colorant, flavoring agent, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier, etc., approved by the relevant government regulatory agency as acceptable for use in humans or veterinary animals.

[0042] According to the present invention, the pharmaceutical product prepared for the above-mentioned use may contain, as an active ingredient, a drug that can be used for the prevention or treatment of autoimmune diseases and immune-related inflammatory skin diseases, in addition to the small molecule compound according to the present invention. Examples of the drug include, but are not limited to, vitamin D derivatives, vitamin A derivatives, glucocorticoids, calcineurin inhibitors, nonsteroidal anti-inflammatory agents, etc. When the drug contains multiple active ingredients, each active ingredient may be administered simultaneously, sequentially, or separately, according to the doctor's judgment.

[0043] Meanwhile, the small molecule compounds of the present invention can be administered to patients by various routes, such as oral, transdermal, subcutaneous, intranasal, intravenous, intramuscular, intrathecal, regional or local (e.g., mucosal). The optimal route of administration in any given case is determined by the subject and the nature and severity of the disease, and the physical condition of the subject. In one embodiment, the small molecule compounds of the present invention can be administered intravenously. In another embodiment, the small molecule compounds of the present invention can be administered orally. Thus, depending on the different administration modes, the pharmaceutical preparations according to the present invention can be prepared in different dosage forms. For example, in one embodiment, the pharmaceutical preparations can be prepared as tablets, capsules, pills, granules, nebulizers, sprays, or injections.

[0044] Through research, it has been found that the small molecule compound of the present invention or the medicine prepared therewith can exert excellent effects when used for preventing or treating JAK-related autoimmune disease and immune-related inflammatory skin disease.Specifically, the autoimmune disease includes but is not limited to rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, Crohn's disease, systemic lupus erythematosus, dermatomyositis, multiple sclerosis, type I diabetes, Sjogren's syndrome, and vasculitis; the immune-related inflammatory skin disease includes but is not limited to atopic dermatitis, eczema, alopecia areata, psoriasis or vitiligo, lichen planus, lichen nitidus, lichen scleroatrophicus, panniculitis, acne, and hidradenitis suppurativa.

[0045] The effects of specific small molecule compounds of the present invention will be described in detail below through examples. EXAMPLES

[0046] <Example 1: General synthesis method of compound 1 (TDM-180973)> [ka] Step 1: Preparation of compound 1c (2-chloro-4-(1H-pyrrol-3-yl)pyrimidine) Compound 1a (2 g, 13.43 mmol), compound 1b (4.69 g, 13.43 mmol), tetrakis(triphenylphosphine)palladium (940 mg, 1.08 mmol), potassium carbonate (3.7 g, 26.85 mmol), dioxane (120 mL) and water (120 mL) were added to a 250 mL three-neck flask. After replacing the reaction liquid with nitrogen several times, the temperature was raised to 80° C. and the reaction was continued for 45 minutes. LCMS [M+H] + = 180, the completion of the reaction is detected. Work-up: The reaction solution is concentrated to dryness, and the obtained crude product is passed through a column [eluent: (EA / PE) = 0-30%] to obtain the target compound (compound 1c, 1.13 g, yield 46.86%) as a yellow solid. LCMS [M+1] + = 180.

[0047] Step 2: Preparation of compound 1e (3-(3-(2-chloropyrimidin-4-yl)-1H-pyrrol-1-yl)-3-(cyanomethyl)azetidine-1-carboxylic acid tert-butyl ester) Compound 1d (1.47 g, 7.56 mmol) and 1,8-diazabicycloundec-7-ene (710 mg, 4.68 mmol) were added to a solution of compound 1c (1.23 g, 6.88 mmol) in acetonitrile (100 ml), and the reaction mixture was heated to 70° C. and stirred for 2 hours. LCMS [M+H] += 374, the completion of the reaction was detected. Work-up: The reaction solution was concentrated to dryness, and the obtained crude product was passed through a column [eluent: (EA / PE) = 0-30%] to obtain the target compound (compound 1e, 2.085 g, yield 81.09%) as a yellow solid. LCMS [M+H] + = 374.

[0048] Step 3: Preparation of compound 1f (2-(3-(3-(2-chloropyrimidin-4-yl)-1H-pyrrol-1-yl)azetidin-3-yl)acetonitrile) To a solution of compound 1e (1.6 g, 4.3 mmol) in dichloromethane (128 ml), trifluoroacetic acid (25.6 ml) was added, and the reaction mixture was stirred at room temperature for 1 hour. LCMS [M+H] + = 274, the completion of the reaction is detected. Work-up: The reaction solution is neutralized with triethylamine in an ice bath, concentrated to dryness, and the obtained crude product is passed through a column [eluent: (D / M = 10 / 1): DCM = 0-50%] to obtain the target compound (compound 1f, 950 mg, yield 89.7%) as a yellow solid. LCMS [M+H] + = 274.

[0049] Step 4: Preparation of compound 1h ((S)-2-(3-(3-(2-chloropyrimidin-4-yl)-1H-pyrrol-1-yl)-1-(2,2-difluorocyclopropane-1-carbonyl)azetidin-3-yl)) To a solution of compound 1f (1 g, 3.65 mmol) in N,N-dimethylformamide (100 ml) was added 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (2.78 g, 7.3 mmol), N,N-diisopropylethylamine (5 g, 7.3 mmol) and compound 1g (450 mg, 3.65 mmol). The reaction was stirred at room temperature for 1 hour and analyzed by LCMS [M+H + = 378, the completion of the reaction was detected. Work-up: The reaction solution was concentrated to dryness, and the obtained crude product was passed through a column [eluent: (EA / PE) = 0-50%] to obtain the target compound (compound 1h, 1120 mg, yield 81.16%) as a yellow solid. LCMS[M+H] + = 378.

[0050] Step 5: Preparation of compound 1 ((S)-4-((4-(1-(3-(cyanomethyl)-1-(2,2-difluorocyclopropane-1-carbonyl)azetidin-3-yl)-1H-pyrrole-)3-yl)pyrimidin-2-yl)amino)-N-ethylbenzamide) Compound 1i (104 mg, 0.64 mmol) and p-toluenesulfonic acid monohydrate (120.8 mg, 0.64 mmol) are added to a solution of compound 1h (120 mg, 0.317 mmol) in n-butanol (20 ml). The reaction solution is heated to 110° C. and stirred for 2 hours. LCMS [M+H] + The completion of the reaction was detected at 506° C. Post-treatment: The reaction solution was concentrated to dryness to obtain the target compound (Compound 1, 29 mg, yield 18.1%) as a white solid. LCMS [M+H + = 506.2. 1 H NMR (400 MHz, DMSO)δ 9.71(s, 1H), 8.41(d, J = 5.3 Hz, 1H), 8.25(t, J = 5.5 Hz, 1H), 7.95 - 7.86(m, 3H), 7.79(d, J = 8.8 Hz, 2H), 7.25 - 7.10 (m, 2H), 6.84 (dd, J = 2.9, 1.6 Hz, 1H), 4.71 (ddd, J = 52.1, 41.5, 9.6 Hz, 2H), 4.48 - 4.19 (m, 2H), 3.60 (s, 2H), 3.30 - 3.22(m, 2H), 2.79(dq, J = 13.2, 8.8 Hz, 1H), 2.00 - 1.84(m, 2H), 1.12(t, J = 7.2 Hz, 3H).

[0051] <Example 2: General synthesis method of compound 2 (TDM-180975)> [ka] Step 1: Preparation of compound 2b (3-methyl-5-nitropicolylamide) A mixture of compound 2a (3 g, 18.4 mmol) and concentrated sulfuric acid (18 ml) was heated to 80° C. and stirred for 25 minutes. LCMS [M+H] + = 182, the reaction is complete. Workup: The reaction solution is cooled to room temperature, poured into ice water (100 ml), the pH is adjusted to neutral with sodium carbonate, the mixture is extracted three times with ethyl acetate (3 x 100 ml), the organic phases are combined, washed with saturated saline, dried over anhydrous sodium sulfate, suction filtered, concentrated and dried to obtain the yellow target compound (compound 2b, 3.33 g, yield 94.2%). LCMS[M+1] + = 182.

[0052] Step 2: Preparation of compound 2c (5-amino-3-methylpicolylamide) Under nitrogen protection, palladium on carbon (10%, 300 mg) was added to a solution of compound 2b (3.14 g, 17.33 mmol) in methanol (150 ml), and the mixture was purged with hydrogen under vacuum several times, and the reaction mixture was stirred at room temperature under a hydrogen balloon for 2 hours. LCMS [M+H] + The completion of the reaction is detected at 152° C. Post-treatment: The reaction solution is filtered to remove palladium carbon, the filtrate is concentrated to dryness, and the resulting crude product is recrystallized to obtain the target compound (compound 2c, 2.3 g, yield 87.8%) as a white solid. LCMS [M+1] + = 152.

[0053] Step 3: Preparation of compound 2 ((S)-5-((4-(1-(3-(cyanomethyl)-1-(2,2-difluorocyclopropane-1-carbonyl)azetidin-3-yl)-1H-pyrrole-)3-yl)pyrimidin-2-yl)amino)-3-methylpyridineamide) Compound 2c (120 mg, 0.79 mmol) and p-toluenesulfonic acid monohydrate (151 mg, 0.79 mmol) were added to a solution of compound 2d (150 mg, 0.397 mmol) in n-butanol (15 ml). The reaction was heated to 110° C. and stirred for 7 hours. LCMS [M+H] += 493, the reaction is complete. Workup: The reaction solution is concentrated to dryness, the residue is extracted with water and ethyl acetate (3 x 30 ml), the organic phases are combined, washed with saturated saline, dried over anhydrous sodium sulfate, suction filtered, and dried to prepare the crude product to obtain the target compound (compound 2, 7.9 mg, yield 4.04%) as an off-white solid. LCMS[M+H] + = 493.2. 1 H NMR (400 MHz, DMSO) δ 9.89(s, 1H), 8.80(s, 1H), 8.44(d, J = 5.3 Hz, 1H), 8.32(s, 1H), 7.89(d, J = 21.0) Hz, 2H), 7.26 ~ 7.15(m, 3H), 6.84(dd, J = 2.9, 1.6 Hz, 1H), 4.71(ddd, J = 53.5, 41.8, 9.6 Hz, 2H), 4.46 ~ 4.24(m, 2H), 3.58(d, J = 16.7 Hz, 2H), 2.78(dt, J = 11.7, 8.9 Hz, 1H), 2.61(s, 3H), 2.00 - 1.84(m, 2H).

[0054] <Example 3: General synthesis method of compound 3 (TDM-180976)> [ka] Step 1: Preparation of compound 3b (ethyl 3-methyl-5-nitrolinoleate) Slowly add concentrated sulfuric acid (40 ml) to the ethanol (160 ml) solution at 0° C., add compound 3a (4 g, 24.5 mmol) in batches to the reaction solution, heat the reaction solution to reflux, and stir for 72 hours. LCMS [M+H] + = 211, the reaction is complete. Workup: The reaction solution is cooled to room temperature, poured into water (50 ml), extracted three times with ethyl acetate (3 x 50 mL), the organic phases are combined, washed with saturated saline, dried over anhydrous sodium sulfate, suction filtered, and concentrated to dryness to obtain the yellow target compound (compound 3b, 3.73 g, yield 72.56%). LCMS[M+1] + = 211.

[0055] Step 2: Preparation of compound 3c (3-methyl-5-nitrolinoleic acid) To a solution of compound 3b (4.2 g, 20.03 mmol) in tetrahydrofuran (200 ml), a 1N solution of sodium hydroxide (120 ml, 120.16 mmol) was added, and the reaction mixture was stirred at room temperature for 1 hour. LCMS [M+H] + = 183, the reaction completion is detected. Work-up: The reaction solution is slowly poured into ice water (30 ml), the aqueous phase is extracted twice with dichloromethane (2 x 15 mL), the aqueous phase is adjusted to pH = 5-6 with 1N dilute hydrochloric acid, extracted three times with ethyl acetate (3 x 15 mL), the organic phase is combined, washed with saturated saline, dried over anhydrous sodium sulfate, suction filtered, concentrated to dryness, and the crude product is recrystallized to obtain the target compound (compound 3c, 3.0 g, yield 82.19%) as a yellow solid. LCMS [M+1] + = 183.

[0056] Step 3: Preparation of compound 3e (N,3-dimethyl-5-nitrolinoleamide) To a solution of compound 3c (3.0 g, 16.48 mmol) in N,N-dimethylformamide (100 ml) was added 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (10.03 g, 26.37 mmol), N,N-diisopropylethylamine (7.5 g, 57.68 mmol) and compound 3d (2.26 g, 32.96 mmol). The reaction was stirred at room temperature for 1 hour and LCMS [M+H] + = 196, the completion of the reaction was detected. Work-up: The reaction solution was concentrated to dryness, and the obtained crude product was passed through a column [eluent: (EA / PE) = 0-30%] to recrystallize the crude product to obtain the target compound (compound 3e, 3.0 g, yield 93.75%) as a yellow solid. LCMS [M+1] + = 196.

[0057] Step 4: Preparation of compound 3f (5-amino-N,3-dimethylpyridinecarboxamide) Under nitrogen protection, palladium on carbon (10%, 350 mg) was added to a solution of compound 3e (3.5 g, 17.9 mmol) in methanol (200 ml), and the mixture was purged with hydrogen under vacuum several times. The reaction mixture was stirred at room temperature under a hydrogen balloon for 2 hours. LCMS [M+H] + The completion of the reaction was detected at 166° C. Post-treatment: The reaction solution was filtered to remove palladium carbon, and the filtrate was concentrated to dryness. The resulting crude product was passed through a column [eluent: (D / M=10 / 1): DCM=0-10%] and recrystallized to obtain the target compound (compound 3f, 1.8 g, yield 60.87%) as a yellow solid. LCMS [M+1] + = 166.

[0058] Step 5: Preparation of compound 3 ((S)-5-((4-(1-(3-(cyanomethyl)-1-(2,2-difluorocyclopropane-1-carbonyl)azetidin-3-yl)-1H-pyrrol-3-yl)pyrimidin-2-yl)amino)-N,3-dimethylpyridinecarboxylic acid amide) Compound 3f (131.2 mg, 0.79 mmol) and p-toluenesulfonic acid monohydrate (151.03 mg, 0.79 mmol) were added to a solution of compound 3g (150 mg, 0.40 mmol) in n-butanol (35 ml). The reaction was heated to 110° C. and stirred for 7 hours. LCMS [M+H] + = 507, the reaction is complete. Workup: The reaction solution is concentrated to dryness, the residue is extracted with water and ethyl acetate (3 x 30 ml), the organic phases are combined, washed with saturated saline, dried over anhydrous sodium sulfate, suction filtered, and dried to prepare the crude product, which is an off-white solid of the desired compound (compound 3, 6.8 mg, yield 3.38%). LCMS[M+1] + = 507.2. 1H NMR (400 MHz, DMSO)δ 9.88(s, 1H), 8.82(d, J = 2.3 Hz, 1H), 8.45(dd, J = 8.9, 4.8 Hz, 2H), 8.30(s, 1H), 7.91(s, 1H), 7.32 - 7.10(m, 2H), 6.83(dd, J = 2.9, 1.6 Hz, 1H), 4.71(ddd, J = 53.5, 41.7, 9.6 Hz, 2H), 4.48 - 4.19(m, 2H), 3.60(s, 2H), 2.82 - 2.70(m, 4H), 2.61(s, 3H), 1.97 - 1.85(m, 2H).

[0059] <Example 4: General synthesis method of compound 4 (TDM-180978)> [ka] Step 1: Preparation of compound 4 ((S)-4-((4-(1-(3-(cyanomethyl)-1-(2,2-difluorocyclopropane-1-carbonyl)azetidin-3-yl)-1H-pyrrole-)3-yl)pyrimidin-2-yl)amino)-N-ethyl-2-methylbenzamide) Prepared in a similar manner to give compound 4 (off-white solid, 16.8 mg, 4.3% yield). 1H NMR (400 MHz, DMSO)δ 9.52(s, 1H), 8.38(d, J = 5.2 Hz, 1H), 8.05(t, J = 5.6 Hz, 1H), 7.87(t, J = 1.8 Hz, 1H), 7.74(d, J = 2.5 Hz, 1H), 7.69(d, J = 8.5 Hz, 1H), 7.29(d, J = 8.4 Hz, 1H), 7.23 - 7.14(m, 1H), 7.10(dd, J = 5.2, 3.8 Hz, 1H), 6.83(dd, J = 2.9, 1.6 Hz, 1H), 4.71(ddd, J = 53.1, 42.0, 9.6 Hz, 2H), 4.48 - 4.19(m, 2H), 3.60(s, 2H), 3.26 - 3.17(m, 2H), 2.79(dd, J = 12.3, 9.6 Hz, 1H), 2.34(d, J = 13.1 Hz, 3H), 1.93(dd, J = 17.3, 9.3 Hz), 2H), 1.11(t, J = 7.2 Hz, 3H). LCMS [M+H] + =520.2.

[0060] <Example 5: General synthesis method of compound 5 (TDM-180996)> [ka] Step 1: Preparation of compound 5 (2-1-((S)-2,2-difluorocyclopropane-1-carbonyl)-3-(3-(2-((6-(1-hydroxypropane-2-basic)pyridin-3-yl)amino)pyrimidin-4-yl)-1H-pyrrol-1-yl)azetidin-3-yl)acetonitrile) Prepared in a similar manner to give compound 5 (off-white solid, 19.2 mg, 7.35% yield). 1H NMR(401 MHz, DMSO)δ 9.50(s, 1H), 8.81(d, J = 2.5 Hz, 1H), 8.36(d, J = 5.3 Hz, 1H), 8.21(d, J = 8.5 Hz, 1H), 8.15(s, 1H), 7.87(s, 1H), 7.17(dd, J = 8.3, 5.6 Hz, 2H), 7.10(dd, J = 5.2, 4.0 Hz, 1H), 6.81(dd, J = 2.8, 1.6 Hz, 1H), 4.75(dt, J = 18.0, 9.6 Hz, 2H), 4.58(d, J = 9.5 Hz, 1H), 4.42(dd, J = 10.6, 5.9 Hz, 1H), 4.36 - 4.21(m, 1H), 3.68 - 3.57(m, 3H), 3.48(dd, J = 10.2, 7.0 Hz, 1H), 2.90(dd, J = 13.7, 6.9 Hz, 1H), 2.83 - 2.72(m, 1H), 1.99 - 1.81(m, 2H), 1.19(d, J = 6.9 Hz, 3H). LCMS [M+H] + =494.2.

[0061] <Example 6: General synthesis method of compound 6 (TDM-180982)> [ka] Step 1: Preparation of compound 6c (3-(cyanomethyl)-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-1-yl)azetidine-1-carboxylic acid tert-butyl ester) Compound 6b (2 g, 10.3 mmol) and 1,8-diazabicycloundec-7-ene (1 mL, 10.3 mmol) were added to a mixture of compound 6a (2 g, 10.3 mmol) in acetonitrile (40 mL) at room temperature, and the mixture was heated to 70 °C and stirred overnight. After the reaction was completed, the mixture was concentrated under reduced pressure, and the residue was purified by silica gel chromatography (petroleum ether / ethyl acetate = 0% to 50%) to obtain the target compound (compound 6c, 2.42 g, yield 60.5%) as a white solid. LCMS [M-C4H9] + = 333.2.

[0062] Step 2: Preparation of compound 6e (3-(4-(2-chloropyrimidin-4-yl)-1H-pyrazol-1-yl)-3-(cyanomethyl)azetidine-1-carboxylic acid tert-butyl ester) To a mixture of compound 6d (2.13 g, 5.486 mmol), compound 6c (1.31 g, 8.777 mmol), sodium carbonate (1.16 g, 10.972 mmol), and 1,1'-bisdiphenylphosphinoferrocenedichloropalladium (401 mg, 0.549 mmol), dioxane (120 ml) and water (20 ml) were added, and the mixture was purged with nitrogen several times, then heated to 80°C and stirred for 1 hour. The mixture was concentrated under reduced pressure, and the residue was purified by silica gel chromatography (petroleum ether / ethyl acetate = 0% to 42%) to obtain the target compound (compound 6e, 1.67 g, yield 81.2%) as a pale yellow solid. LCMS[M+H] + = 375.

[0063] Step 3: Preparation of compound 6f (2-(3-(4-(2-chloropyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile) Trifluoroacetic acid (16 ml) is added dropwise to a solution of compound 6e (1.4 g, 3.735 mmol) in dichloromethane (80 ml), and the mixture is stirred at room temperature for 1 hour. After the reaction is completed, water is added to the mixture, neutralized with aqueous sodium hydroxide solution, extracted with dichloromethane (80 ml x 3), the organic layers are combined, washed with saturated saline (100 ml), dried over sodium sulfate, the filtrate is concentrated under reduced pressure, and the residue is purified by silica gel chromatography (dichloromethane / dichloromethane solution containing 10% methanol = 0% to 100%) to obtain the target compound (compound 6f, 571.1 mg, yield 55.7%) as a white solid. LCMS[M+H] + = 275.

[0064] Step 4: Preparation of compound 6h ((S)-2-(3-(4-(2-chloropyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(2,2-difluorocyclopropane-1-carbonyl))azetidin-3-yl)acetonitrile) To a solution of compound 6g (293.3 mg, 2.403 mmol) in N,N-dimethylformamide (30 ml), add 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (913.7 mg, 2.403 mmol) and N,N-diisopropylethylamine (776.2 mg, 3.003 mmol), stir the mixture for 5 minutes, then add compound 6f (550 mg, 2.002 mmol), and stir the mixture at room temperature for 1 hour. After the reaction is complete, add water and extract with ethyl acetate (50 ml x 3), wash the combined organic layers with water (50 mL x 3) and saturated saline (50 ml), dry over sodium, concentrate the filtrate under reduced pressure, and purify the residue by silica gel chromatography (petroleum ether / ethyl acetate = 0% to 50%) to obtain the target compound (compound 6h, 566 mg, yield 74.6%) as a white solid. LCMS[M+H] + = 379.

[0065] Step 5: Preparation of compound 6 ((S)-4-((4-(1-(3-(cyanomethyl)-1-(2,2-difluorocyclopropane-1-carbonyl)azetidin-3-yl)-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)-N-ethylbenzamide) Compound 6i (43.4 mg, 0.264 mmol) and p-toluenesulfonic acid monohydrate (50.2 mg, 0.264 mmol) are added to a solution of compound 6h (50 mg, 0.132 mmol) in n-butanol (5 ml). The resulting mixture is heated to 110° C. and stirred for 3 h. The mixture is concentrated under reduced pressure, and the residue is purified by preparative HPLC (formic acid) to obtain the target compound TDM-180982 (compound 6, 11.4 mg, 17.1% yield) as a white solid. LCMS[M+H] + = 507.2. 1H NMR(400 MHz, DMSO)δ 9.85(s, 1H), 8.86(d, J = 4.6 Hz, 1H), 8.51(d, J = 5.2 Hz, 1H), 8.32(s, 1H), 8.27(t, J = 5.5 Hz, 1H), 7.90(d, J = 8.8 Hz, 2H), 7.81(d, J = 8.8 Hz, 2H), 7.23(dd, J = 5.2, 1.4 Hz, 1H), 4.86(dd, J = 35.3, 9.6 Hz, 1H), 4.67(dd, J = 41.8, 9.6 Hz, 1H), 4.51(t, J = 9.9 Hz, 1H), 4.31(t, J = 10.2 Hz, 1H), 3.72(d, J = 2.8 Hz, 2H), 3.30 - 3.23(m, 2H), 2.90 - 2.74(m, 1H), 1.92(qd, J = 11.0, 7.4 Hz, 2H), 1.12(t, J = 7.2Hz, 3H).

[0066] <Example 7: General synthesis method of compound 7 (TDM-180983)> [ka] Step 1: Preparation of compound 7 ((S)-5-((4-(4-(4-(2,2-difluorocyclopropane-1-carboxamido)phenyl)pyrimidin-2-yl)amino)-N,3-dimethylpyridineamide) Prepare compound 7 (white solid, 12.7 mg, 14.5% yield) in a similar manner. 1H NMR (400 MHz, DMSO)δ 9.66(s, 1H), 8.84(d, J = 4.2 Hz, 1H), 8.49(d, J = 5.2 Hz, 1H), 8.30(s, 1H), 8.06(t, J=5.6Hz, 1H), 7.73 - 7.65(m, 2H), 7.34 - 7.27(m, 1H), 7.19(dd, J=5.1, 1.9Hz, 1H), 4.84(dd, J=34.2, 9.6Hz), 1H), 4.66(dd, J = 42.4, 9.5 Hz, 1H), 4.49(t, J = 10.3 Hz, 1H), 4.30(t, J = 10.2 Hz, 1H), 3.72(d, J = 1.8 Hz, 2H), 3.27 - 3.16(m, 2H), 2.82(ddd, J = 19.2, 12.0, 9.0 Hz, 1H), 2.36(s, 3H), 2.00 - 1.85(m, 2H), 1.11(t, J = 7.2 Hz, 3H). LCMS[M+H] + =521.1.

[0067] <Example 8: General synthesis method of compound 8 (TDM-180985)> [ka] Step 1: Preparation of compound 8 ((S)-5-((4-(1-(3-(cyanomethyl)-1-(2,2-difluorocyclopropane-1-carbonyl)azetidin-3-yl)-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)-N,3-dimethylpyridine carboxylic acid amide) Compound 8b (85 mg, 0.517 mmol) and p-toluenesulfonic acid monohydrate (98 mg, 0.517 mmol) are added to a solution of compound 8a (80 mg, 0.258 mmol) in n-butanol (8 mL). The resulting mixture is heated to 115° C. and stirred overnight. After the reaction is complete, the mixture is cooled to room temperature, water is added, and the mixture is extracted with ethyl acetate (30 ml×3). The organic layers are combined, washed with saturated saline (50 ml), dried over sodium sulfate, the filtrate is concentrated under reduced pressure, and the residue is purified by preparative HPLC (formic acid) to obtain the target compound TDM-180985 (compound 8, 10.2 mg, 6.2% yield) as an off-white solid. LCMS [M+H] + =508.2. 1 H NMR (400 MHz, DMSO) δ 10.01(s, 1H), 8.88(d, J = 4.5 Hz, 1H), 8.81(d, J = 2.3 Hz, 1H), 8.55(d, J = 5.2 Hz, 1H), 8.46(d, J = 4.8 Hz, 1H), 8.30(s, 1H), 8.27(d, J = 2.1 Hz, 1H), 7.28(dd, J = 5.2, 1.9 Hz, 1H), 4.85(dd, J = 33.3, 9.6 Hz, 1H), 4.67(dd, J = 42.3, 9.6 Hz, 1H), 4.49(t, J = 10.4 Hz, 1H), 4.31(t, J = 10.3 Hz, 1H), 3.72(s, 2H), 2.89 - 2.74(m, 4H), 2.61(s, 3H), 2.01 - 1.84(m, 2H).

[0068] <Example 9: General synthesis method of compound 9 (TDM-180986)> [ka] Step 1: Preparation of compound 9 ((S)-5-((4-(1-(3-(cyanomethyl)-1-(2,2-difluorocyclopropane-1-carbonyl)azetidin-3-yl)-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)-3-methylpyridineamide) Prepare in a similar manner to give compound 9 (off-white solid, 10.7 mg, 8.4% yield). 1H NMR (400 MHz, DMSO) δ 10.03(s, 1H), 8.88(d, J = 4.4Hz, 1H), 8.80(d, J = 2.0Hz, 1H), 8.55(d, J = 5.2Hz, 1H), 8.29(d, J = 11.4 Hz, 2H), 7.87(s, 1H), 7.38 - 7.16(m, 2H), 4.85(dd, J = 33.3, 9.6 Hz, 1H), 4.67(dd, J = 42.5, 9.6 Hz, 1H), 4.49(t, J = 10.4 Hz, 1H), 4.31(t, J = 10.2 Hz, 1H), 3.72(s, 2H), 2.90 - 2.75(m, 1H), 2.61(s, 3H), 1.94(d, J = 8.0 Hz, 2H). LCMS[M+H] + = 494.3.

[0069] <Example 10: General synthesis method of compound 10 (TDM-180990)> [ka] Step 1: Preparation of compound 10 (2-(1-((S)-2,2-difluorocyclopropane-1-carbonyl)-3-(4-(2-(((6-(1-hydroxypropan-2-yl))pyridin))-3-yl)amino)pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile) To a mixture of compound 10a (190 mg, 0.502 mmol), compound 10b (153 mg, 1.003 mmol), palladium acetate (11.4 mg, 0.050 mmol), 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene (58.1 mg, 0.1 mmol) and cesium carbonate (461 mg, 1.506 mmol) was added dioxane (40 mL). The mixture was flushed with argon several times and the mixture was heated to 100° C. and stirred for 1 h. After the reaction is completed, water (60 mL) is added to the reaction mixture, and the mixture is extracted with ethyl acetate (60 mL x 3). The organic layers are combined, washed with water (100 mL) and saturated saline (100 mL x 2), dried over sodium sulfate, and the filtrate is concentrated under reduced pressure. The residue is purified by silica gel chromatography (petroleum ether / ethyl acetate = 0% to 70%) and preparative HPLC (formic acid) to obtain the target compound TDM-180990 (compound 10, 76.6 mg, yield 30.9%) as a white solid. LCMS [M+H] + = 495.2. 1 H NMR (400 MHz, DMSO) δ 9.65(s, 1H), 8.85(d, J = 4.3Hz, 1H), 8.79(s, 1H), 8.47(d, J = 5.2Hz, 1H), 8.29(s, 1H), 8.21(dt, J = 8.5, 2.9 Hz, 1H), 8.17(s, 1H), 7.19(dd, J = 10.2, 5.1 Hz, 2H), 4.85(dd, J = 33.3, 9.6 Hz, 1H), 4.66(dd, J = 42.4, 9.6Hz, 2H), 4.50(t, J = 11.0Hz, 1H), 4.30(t, J = 10.2Hz, 1H), 3.71(d, J = 2.8Hz, 2H), 3.63(dd, J=10.2, 6.6Hz, 1H), 3.49(dd, J=10.2, 7.0Hz, 1H), 2.90(dt, J=12.7, 6.4Hz, 1H), 2.81(ddd, J=13.2, 10.4, 6.2Hz, 1H), 2.00 - 1.86(m, 2H), 1.20(d, J = 6.9 Hz, 3H).

[0070] Test Example 1. Enzyme Activity Inhibition Assay of Small Molecule Inhibitors of JAK Kinases Experimental Program 1. Preparation of Reagents Kinase reaction buffer: Prepare kinase reaction buffer, components are as follows: 50 mM HEPES, pH 7.5, 1 mM EGTA, 10 mM MgCl2, 2 mM DTT, 0.01% Tween20.

[0071] 1X Assay Buffer: Prepare assay buffer by diluting 10X assay buffer to 1X with deionized water 9:1.

[0072] 4X Kinase Solution: Dilute JAK kinases to a final concentration of 4X (JAK1: 80 nM, JAK2 / JAK3 / Tyk2: 4 nM) in kinase reaction buffer.

[0073] 4X Substrate Solution: Dilute ULight™-JAK (Tyr1023) substrate to 200 nM (final concentration: 50 nM) in kinase reaction buffer.

[0074] 4X ATP solution: Dilute ATP to a final concentration of 4X (JAK1: 160 μM, JAK2 / JAK3 / Tyk2: 40 μM) in kinase reaction buffer.

[0075] 4X test compound solution: Dissolve test compounds in DMSO to a 10 mM stock solution and dilute in a 3-fold gradient to the required concentration. Ten concentration points are set for each compound, with the final test compound concentration range being 10 μM-0.5 nM.

[0076] 4X Enzyme Reaction Stop Solution: Dissolve EDTA to 40 mM (EDTA final concentration: 10 mM) in 1X Assay Buffer.

[0077] 4X Assay Antibody Solution: Dilute Eu-labeled assay antibody (anti-phosphorylated tyrosine (PT66)) to 8 nM (final concentration of antibody: 2 nM) in 1X Assay Buffer.

[0078] 2. Experimental process 2.5μL of 4X kinase solution and 2.5μL of diluted 4X test compound solution of different concentrations are added to a 384 microwell plate in sequence, with two replicate wells for each concentration, and a blank control group and a negative control group (DMSO group) for the enzyme solution are set up at the same time. The 384-well plate is shaken to mix the enzyme and compound, centrifuged at 1000rpm for 1 minute, and incubated at room temperature for 60 minutes. 2.5μL of 4X substrate solution is added to the 384-well plate, and centrifuged at 1000rpm for 1 minute. 2.5μL of 4X ATP solution is added to the 384-well plate, and centrifuged at 1000rpm for 1 minute to start the enzyme reaction. JAK1 is reacted at room temperature for 2 hours, and JAK2 / JAK3 / Tyk2 is reacted at room temperature for 1 hour. The final concentrations of each component of the JAK1 reaction are JAK1: 20 nM, substrate: 50 nM, ATP: 40 uM, and the final concentration range of the test compound is 10 μM-0.5 nM. The final concentrations of each component of the JAK2 / JAK3 / Tyk2 reaction are JAK2: 1 nM, substrate: 50 nM, ATP: 10 μM, and the final concentration range of the test compound is 10 μM-0.5 nM. After the enzyme reaction is complete, add 5 μL of 4X enzyme reaction stop solution to each well of the 384-well plate, centrifuge at 1000 rpm for 1 minute, and incubate at room temperature for 5 minutes. Add 5 μL of 4X assay antibody solution to each well of the 384-well plate (final concentration of assay antibody is 2 nM), centrifuge at 1000 rpm for 1 minute, and incubate at room temperature for 1 hour. After antibody incubation, measure the signal value of each well with an Envision plate reader.

[0079] 3. Data Analysis The inhibition rate corresponding to each concentration was calculated by setting the blank control group of the enzyme solution as 100% inhibition rate and the negative control group (DMSO group) as 0% inhibition rate. A nonlinear regression analysis was performed on the logarithm of the concentration of the assay compound and the corresponding percent inhibition rate using GraphPad Prism software to calculate the half inhibitory concentration (IC 50 The experimental results obtained with the compounds of Examples 1 to 10 are shown in Table 1 below.

[0080] [Table 1]

[0081] As can be seen from the results in Table 1 above, the compounds of the present application have excellent enzyme activity data, and the half-inhibitory concentrations measured for the specific compounds are low, especially for Tyk2, JAK1 and JAK2, which are basically 0.01 to about 0.1 μM, and especially for compounds TDM-180973, TDM-180975, TDM-180976 and TDM-180978, the half-inhibitory concentrations are all about 0.01 μM. Therefore, the above experiments prove that the small molecule compounds of the present application are compounds with strong targeting to the JAK family and excellent enzyme activity, and can be used as JAK1 / Tyk2 dual inhibitors and Tyk2 specific inhibitors.

[0082] Although the preferred embodiments of the present invention have been described in detail above, the present invention is not limited to the specific contents of the above embodiments. Various simple modifications can be made to the technical solutions of the present invention within the scope of the technical idea of ​​the present invention, and all such simple modifications fall within the protection scope of the present invention.

[0083] It should be further noted that the various specific technical features described in the above specific embodiments may be combined in any suitable manner unless contradictory, and in order to avoid unnecessary duplication, the present invention does not separately describe the various possible combination forms.

[0084] Furthermore, any combination between the various different embodiments according to the present invention is possible, and unless contrary to the spirit of the present invention, such combinations should also be considered as the disclosure of the present invention.

Claims

1. A small molecule compound, characterized in that it is a compound represented by the following formula I, or a stereoisomer, geometric isomer, tautomer, hydrate, solvate, or pharma- ceutically acceptable salt thereof: 【Chemistry 1】 Where: R 1 ~R 5 are each independently selected from C or N; R has a structure represented by Formula II or Formula III shown below: 【Chemistry 2】 Where: R 6 is selected from C or N; R 7 is selected from hydrogen, halogen, alkyl, amino, amido, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R 8 is selected from hydrogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R 9 is selected from C or N; R 10 is selected from hydrogen, halogen, alkyl, amino, amido, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R 11 is selected from hydrogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl.

2. R 1 ~R 5 The small molecule compound of claim 1, wherein up to two of are N.

3. R 7 and R 8 The small molecule compound of claim 1 , wherein each is independently selected from hydrogen, alkyl, or cycloalkyl.

4. R 10 and R 11 The small molecule compound of claim 1 , wherein each is independently selected from hydrogen, alkyl, or cycloalkyl.

5. 5. The small molecule compound of claim 3 or 4, characterized in that the alkyl group is methyl, ethyl, propyl or isopropyl, and the cycloalkyl group is cyclopropyl, cyclobutyl or cyclopropylmethyl.

6. A drug comprising the small molecule compound of any one of claims 1 to 5 for inhibiting a JAK kinase.

7. A drug for preventing or treating autoimmune diseases and immune-related inflammatory skin diseases, the pathogenesis of which is both associated with dysregulation of JAK signaling, comprising a small molecule compound according to any one of claims 1 to 5.

8. 8. The method of claim 7, wherein the autoimmune disease is selected from at least one of rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, Crohn's disease, systemic lupus erythematosus, dermatomyositis, multiple sclerosis, type I diabetes, Sjogren's syndrome, and vasculitis.

9. 8. The method of claim 7, wherein the immune-related inflammatory skin disease is selected from at least one of atopic dermatitis, eczema, alopecia areata, psoriasis, vitiligo, lichen planus, lichen nitidus, lichen sclerosus, panniculitis, acne, and hidradenitis suppurativa.

Citation Information

Patent Citations

  • Small molecule compound

    CN110734428A

  • Small molecule compound

    CN110862376A

  • Small molecule compounds

    CN110862380A

  • Substitutive heterocycles as JANUS kinase inhibitors

    JP2011503194A

  • Bipyrazole derivatives as jak inhibitors

    JP2016519147A